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step, providing a new platform for
synthesis of complex natural products
and unnatural derivatives.
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Macrocyclases and other posttranslational enzymes
afford derived peptides with improved properties for
pharmaceutical and biotechnological applications.
Here, we asked whether multiple posttranslational
modifications could be simultaneously controlled
and matched to rationally generate new peptide
derivatives. We reconstituted the cyanobactin pep-
tide natural products in vitro with up to five different
posttranslational enzymes in a single tube. By
manipulating the order of addition and identity
of enzymes and exploiting their broad-substrate
tolerance, we engineered the production of highly
unnatural derivatives, including an N-C peptide
macrocycle of 22 amino acids in length. In addition
to engineering, this work better defines the macro-
cyclization mechanism, provides the first biochem-
ical demonstration of Ser/Thr posttranslational
prenylation, and is the first example of reconstitution
of a native, multistep RiPP pathway with multiple
enzymes in one pot. Overall, this work demonstrates
how the modularity of posttranslational modification
enzymes can be used to design and synthesize
desirable peptide motifs.
INTRODUCTION
Cyclic peptides are of particular interest among the various
bioactive macrocyclic scaffolds known so far. Their stability,
coupled with their ability to access hard to reach targets
such as protein-protein interactions, has led to significant
enthusiasm concerning their therapeutic potential (White and
Yudin, 2011). Most cyclic peptide drugs approved by the US
Food and Drug Administration, such as cyclosporine and
daptomycin, are synthesized by non-ribosomal multienzyme
assembly lines (Sieber and Marahiel, 2003), but an increasing
number of related cyclic compounds are also ribosomally
synthesized (Arnison et al., 2013). The chemical synthesis of
macrocyclic scaffolds has been well explored, but many draw-
backs exist including those of specific sequence requirements,
length restrictions, poor yield, and high cost (Yu and Sun,
2013). In contrast, enzyme-catalyzed peptide macrocyclization
offers many advantages over the conventional synthetic chem-
istry methods.Chemistry & Biology 22,Well-studied enzymatic N-C macrocyclizations include those
mediated by subtiligases, sortases, and inteins (Zhang et al.,
2014; Scott et al., 1999). In contrast to these unnatural pro-
cesses, PatG-like enzymes from cyanobactin pathways are
serine proteases that natively form macrocycles (Lee et al.,
2009; McIntosh et al., 2010; Agarwal et al., 2012; Koehnke
et al., 2012). The macrocyclases creating the cyclotide and
amanitin natural products are also being explored (Craik and
Malik, 2013; Luo et al., 2012, 2014; Barber et al., 2013; Nguyen
et al., 2014). In addition, a wide array of enzymes cyclizing prod-
ucts via side chains (rather than asmain-chain N-Cmacrocycles)
is also known (Arnison et al., 2013). Beyond simple synthesis of
macrocycles, it is desirable to introduce tailoring reactions,
which greatly modify the pharmacological properties of the
peptides. In light of this, the aim of this study was to exploit
a series of cyanobactin tailoring enzymes to produce highly
modified cyclic peptides in vitro, using hybrid biosynthetic
machineries comprising mixtures of enzymes from different
pathways.
The cyanobactins are a class of natural products first isolated
frommarine ascidian animals (Ireland and Scheuer, 1980), where
they are produced by symbiotic cyanobacteria (Schmidt et al.,
2005). Cyanobactins are found in approximately 10%–30% of
all cyanobacteria on Earth (Leikoski et al., 2013), creating an
enormous wealth of enzymes and substrates that can be ex-
ploited in synthetic biology. They are ribosomally synthesized
and posttranslationally modified peptides (RiPPs) that aremostly
cyclic, although some linear derivatives have been reported
recently (Leikoski et al., 2013; Donia and Schmidt, 2011). The
biosynthetic pathway involves a linear precursor peptide
substrate, containing a core sequence that matures into the final
natural product. The enzymes that modify the core sequence
include at least two proteases, PatA and PatG and their homo-
logs, which proteolyze the N and C termini of the core sequence,
respectively (Lee et al., 2009). PatG also carries out N-C macro-
cyclization of the core in tandem with proteolysis (Lee et al.,
2009; Schmidt et al., 2005). Often, multiple core peptides are
encoded in a single precursor, such that multiple cyclic peptides
are derived from single substrates. Further modifications such
as heterocyclization, oxidation, prenylation, and/or methylation
may be carried out by additional enzymes (Figure 1).
In nature, cyanobactins exist as large combinatorial libraries,
leading to hundreds of known natural products and probably
thousands of unknown compounds. This diversity arises in
part from hypervariable core sequences, which are tolerated
by exceptionally broad-substrate biosynthetic enzymes (Donia
et al., 2006; Sardar et al., 2014). Broad-substrate tolerance
is possible because the precursor contains specific recognition907–916, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 907
Figure 1. Simplified Schematic of Cyanobactin Biosynthesis
A schematic of cyanobactin biosynthetic machinery showing the leader pep-
tide, core peptide, recognition sequences (RSs), and the posttranslational
enzymes used in this study. ThcD is a heterocyclase that uses RSI to modify
Cys residues to thiazoline. This is followed by the action of proteases PatA
and PatG (or TruG) that use RSII and RSIII to cleave off the N and C termini
of the core peptides, respectively. PatG (or TruG) also carries out macro-
cyclization in tandemwith proteolysis. The prenyltransferases TruF1 and PagF
add isoprene units to the cyclic peptide scaffold and do not require RSs.sequences (RSs) directing enzymes to otherwise hypervariable
cores. RS conservation therefore explains, at least in part, the
observed promiscuity of the posttranslational enzymes (Donia
et al., 2006; Sardar et al., 2014). As elucidated from earlier
work, RSI recruits a heterocyclase enzyme (PatD homolog)
that acts on cysteine, serine, or threonine in a regio- and chemo-
selective manner. RSII and RSIII recruit proteases related to
PatA (N-terminal protease) and PatG (C-terminal protease/
macrocyclase), respectively. Proteolysis cleaves RSs from
the core peptide, enabling ‘‘scarless’’ formation of the desired
cyclic peptide with the recognition elements removed. The only
exception in RS requirements lies in the final enzymatic step
of prenylation, which does not seem to need RSs and instead
recognizes cyclic peptides with diverse sequences (McIntosh
et al., 2011) (Figure S1).
Our previous in vitro effort in cyclic peptide production used
a combination of PatA and PatG to generate eptidemnamide
(an analog of the anticoagulant eptifibatide) (Lee et al., 2009).
Subsequent work focused only on PatG activity using short syn-
thetic substrates as starting material (McIntosh et al., 2010;
Agarwal et al., 2012; Koehnke et al., 2012). These substrates
carried a proline residue at the C terminus of the core, since a
heterocycle at this position was observed to be required for
PatG activity (McIntosh et al., 2010), although natural PatG
substrates carry thiazole at this position. We have also synthe-
sized small libraries in vitro using discrete substrates for the
prenyltransferase enzymes (McIntosh et al., 2011). Despite hav-
ing the ability to reconstitute individual enzymatic steps in vitro,
the combination of multiple enzymatic steps to generate modi-
fied cyclic peptides has been much simpler in Escherichia coli
in vivo (Ruffner et al., 2014; Tianero et al., 2011). Using this
methodology, the single tru pathway has been used to encode
libraries that potentially synthesize millions of ‘‘unnatural natural
products.’’ While in vivo libraries are extremely powerful in drug
discovery, not all types of compounds are readily synthesized.908 Chemistry & Biology 22, 907–916, July 23, 2015 ª2015 Elsevier LFor example, compounds toxic to E. coli are unlikely to be pro-
duced, and substrates that are degraded faster than they are
modified by enzymes would not be observable.
Recent advances in heterocyclization chemistry using PatD
and homologs (Sardar et al., 2014; Koehnke et al., 2013; Goto
et al., 2014) enabled us to make short heterocycle containing
peptides, which provided a simple method to generate native-
like substrates for downstream enzymes in vitro. This in turn
allowed us to optimize the conditions necessary to exploit the
chemistry of a combination of these enzymes. Here, our efforts
involved the coupling of PatD-like enzymes along with a mixture
of other posttranslational enzymes to produce modified cyclic
peptides. We based this work on the hypothesis that the RS
elements act independently both from each other and from
the core peptides. Therefore, appropriately embedded RS ele-
ments would universally and predictively recruit posttransla-
tional modification enzymes, even when mixed from different
biosynthetic pathways. We tested this hypothesis by designing
and synthesizing a series of modified cyclic peptides, both
natural and unnatural, using enzymes, precursors, and RS ele-
ments from the trunkamide, prenylagaramide, cyanothecamide,
patellamide, and aestuaramide cyanobactin families.
RESULTS
Sequential Enzymatic Reactions Reconstitute
Full Pathway Activity
Synthetic substrate 1, which carries the trunkamide core
sequence TSIAPFC (Figure 2), was selected for initial studies
because it exhibited promising biological activity (Salvatella
et al., 2002). In addition, we have developed substantial technol-
ogy around this sequence (Ruffner et al., 2014; Tianero et al.,
2011). In place of the complete precursor peptide, substrate 1
was previously engineered to contain solely RS elements I, II,
and III (Sardar et al., 2014), such that 1 represents aminimal sub-
strate. Precursor 1 was only 25 amino acids in length, enabling
chemical synthesis, whereas the native substrates are >50–80
amino acids and require more cumbersome methods. The
enzymes used included heterocyclase ThcD from the recently
characterized cyanothecamide thc pathway (Donia and
Schmidt, 2011; Houssen et al., 2012; Sardar et al., 2014),
N-terminal protease PatA (Lee et al., 2009), the C-terminal prote-
ase/macrocyclase PatG and TruG (Lee et al., 2009; McIntosh
et al., 2010; Agarwal et al., 2012; Koehnke et al., 2012), and
the prenyltransferase TruF1 (McIntosh et al., 2011), from the
well-characterized patellamide pat and trunkamide tru path-
ways. Although ThcD is not from the tru pathway, it exhibits
the same chemoselectivity as TruD (Sardar et al., 2014).
In addition, PatA and TruA are virtually sequence identical
(Lee et al., 2009).
We investigated the action of enzymes on substrate 1 by
sequentially adding the enzymes into the same tube along with
the necessary enzyme cofactors at each step (see Experimental
Procedures). Since heterocyclization requires RSI, the ThcD
reaction was performed first, leading to the thiazoline-containing
product 2 (Sardar et al., 2014). Subsequent addition of PatA
excised both RSI and the PatA recognition sequence RSII, lead-
ing to products 3 and 4. Since 4 carries thiazoline, it is a substrate
for PatG. Addition of PatG macrocyclase domain to the reactiontd All rights reserved
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Figure 2. In Vitro Synthesis of Trunkamide Derivatives
(A) Schematic representation of the step-by-step reaction starting from the linear unmodified substrate 1 carrying the trunkamide core sequence TSIAPFC along
with the necessary RSs. Action of ThcD heterocyclizes the Cys in the core to lead to 2, followed by proteolysis by N-terminal protease PatA to release the in-
termediate 4, which is further processed by the C-terminal protease/macrocyclase PatG to lead to the cyclic product 5. The addition of the prenyltransferase
TruF1 further prenylates 5 to 6.
(B) Mass spectra showing the masses of each reaction intermediate: 1, 1272.8 Da [M + 2H]2+ and 849.0 Da [M + 3H]3+; 2, 1264.2 Da [M + 2H]2+ and 843.1
[M + 3H]3+; 4, 1084.8 Da [M + H]+ and 543.1 Da [M + 2H]2+; 5, 702.3 Da [M + H]+; and 6, 770.4 Da [M + H]+. See Figure S2 for structures and higher resolution MS
of each species.
(C) Mass spectrum of the [M + H]+ of the product 5 resulting from a one-pot addition of enzymes ThcD, PatA, and PatG. The structure of 5 is given with the
thiazoline modification circled in yellow. See Figure S2G for high-resolution mass spectrum of 5 with a mass error of <2.5 ppm.mixture cleaved the RSIII element in tandem with cyclization to
provide the cyclic peptide 5. The addition of prenyltransferase
TruF1 provided the monoprenylated product 6 (Figures 2 and
S2A). In our hands, only about 30% of 5 (as judged from area
of integrated chromatogram) was converted to the prenylated
product 6, and the doubly prenylated product was not detected
(Figure S2A). The same products 5 and 6were observedwith full-
length protein TruG in place of the macrocyclase/protease
domain of PatG (Figure S2B). The structure of 5 was further
confirmed by nuclear magnetic resonance (NMR) characteriza-
tion (Figure S2C).
The substrate 1 was quantitatively consumed in the reaction,
and less than 5% was converted to side products as detected
by liquid chromatography-mass spectrometry (LC-MS) (Fig-
ure S2D). In the subtiligase and sortase systems, a yield of
67% and 85%, respectively, has been reported (Zhang et al.,
2014), whereas with PatG, as shown here, it is possible to
achieve nearly complete conversion to cyclic product in the
reaction mixture.
Biochemical characterization of each posttranslational
enzyme from previous studies has shown that each enzyme is
fully functional independently, and no protein-protein interac-
tions were detected between enzymes (McIntosh and Schmidt,
2010a, 2010b; McIntosh et al., 2010). Here, we reinvestigated
the possible requirement for protein interactions. ReactionsChemistry & Biology 22,were carried out where intermediates from each step were
purified by high-performance liquid chromatography (HPLC)
and used as a substrate for the next modification step.
These pure intermediates (2 and 4), free from enzymes and
cofactors from the previous modification reaction, were fully
competent substrates for the next enzymatic reaction in that
they could be completely processed to the respective products
(Figure S2E).
Previous studies reported extremely slow reaction rates for
PatG such that in many cases reaction was complete by 24 hr
only with a 50% catalyst load (McIntosh and Schmidt, 2010b;
McIntosh et al., 2010; Agarwal et al., 2012), although the rate
could be modified by adjusting buffer conditions (Koehnke
et al., 2012). In contrast, in this study PatG was comparatively
faster in the formation of product 5 such that complete conver-
sion to product was observed by 24 hr using an enzyme to
substrate ratio of 1:5. To test if the presence of a thiazoline
heterocycle instead of a proline could be responsible for this
acceleration, we synthesized a variant of substrate 1 containing
the same core sequence with a single point mutation of TSIAPFC
to TSIAPFP (1a). Reactions were carried out with PatG to give
the expected cyclic product 5a. A time-course comparison of
amount of proline-containing product 5a formed versus the thia-
zoline-containing product 5 showed that formation of 5a was
significantly slower (up to 4-fold), indicating that presence of907–916, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 909
Figure 3. Synthesis of 22-Ring Size
Macrocycle
Using ThcD and PatG only, macrocycle 8
comprising 22 residues was synthesized from 1.
The structure of 8 is given with the thiazoline
modification shown in yellow along with the high-
resolution FT-ICR mass spectrum showing the
[M + 2H]2+ with an error of <1.5 ppm.the thiazoline at the C-terminal end improved PatG activity
(Figure S2F).
One-Pot Synthesis of Cyanobactins
When all enzymes, cofactors, and the substrate 1 were added
together in one pot rather than sequentially, the cyclic product
5 was readily synthesized (Figures 2 and S2G). As observed for
the sequential reaction, an essentially quantitative conversion
to 5 was measured (Figure S2H). The reaction was sensitive
to the concentration of protease PatA, which could produce
the non-heterocyclized N-terminally cleaved product 7 as a
side product (Figure S2I). Without heterocyclization, 7 is not a
substrate for the macrocyclization reaction. When prenyltrans-
ferase TruF1 was added, the monoprenylated product 6 was
produced (Figure S2J), although as in the sequential reactions
the complete conversion to 6 was not observed. Analysis of
the one-pot reaction showed that the PatG step is the limiting
step in that it is much slower in comparison with either
the ThcD or PatA step (Figure S2K). To our knowledge, this
is the first demonstration of reconstitution of a complete,
multistep RiPP biosynthetic pathway with multiple enzymes in
a single pot.
Unprecedented Macrocycle Size Plasticity
For several years, the ability to perform one-pot reactions eluded
us and has also proved challenging in other hands, where prote-
ases other than PatA were required (Houssen et al., 2014). Here,
we showed that this was due to differential redox sensitivity of
various enzymes in the pathway. Neither ThcD nor PatG require
the addition of reducing agent for activity, but PatA showed a
significant decrease in activity if DTT was used in the assay.
DTT has usually been added to these reactions because of the
prevalence of disulfide bonds in the precursor peptide. Hence,
both the sequential and one-pot reactions described above to
yield 5 were carried out in absence of DTT.
To our surprise, in one-pot reactions with 1 where PatA was
inhibited by DTT, a macrocyclic product (8, m/z = 1,072 Da,910 Chemistry & Biology 22, 907–916, July 23, 2015 ª2015 Elsevier Ltd All rights reserved[M + 2H]2+) was observed, resulting from
macrocyclization of 2 (Figure S3A). This
product could also be recapitulated in
reactions containing solely ThcD and
PatG. The PatG macrocyclase domain
could also be replaced with full-length
TruG, again affording the same product
8 (Figure S3B). Complete conversion of 1
to the product 8 was observed, whether
the reactions were performed in a single
one-pot step (Figure S3C) or via stepwise
addition of enzymes (Figure 3). As with thecyclic peptide 5, the linear derivative of 8 (8 + H2O) was present
only in barely detectable trace amounts.
The structure of 8 was anticipated by high-resolution Fourier
transform ion cyclotron resistance (FT-ICR) tandem mass spec-
trometry (MS/MS) of 8 in comparison with 2, and further
confirmed by purification and NMR analysis (Figures S3D and
S3E; Table S1). Ring opening of the macrocycle as detailed in
the next section provides further evidence confirming the struc-
ture of 8. Purified 8 was quantified by NMR using boc-tyrosine
as a standard (Tianero et al., 2011). This in turn was used to
draw a standard curve of 8, which was used to compute the
yield of the reaction as 81% (Figure S3F). A time course of
the formation of 8 in comparison with 5 in one-pot reactions
is given in Figure S3G. Since this unusually long substrate
2 was macrocyclized, we also examined a short substrate 9,
comprising only 5 amino acids in the core peptide. Substrate 9
was also processed to the cyclic product 11, although with a
lower yield (<40%) (Figure S3H).
Here, we show that pat and tru enzymes can synthesize
macrocycles in a size range of 5–22 amino acids in length.
Previously, natural macrocycles from these pathways were
known to comprise 6–8 amino acids, while artificial substrates
had been 6–11 amino acids long (McIntosh et al., 2010). Beyond
the pat and tru pathways, cyanobactins exist varying from sizes
of as small as 3 residues (the linear products, viridisamides) (Lei-
koski et al., 2013) to up to 20 residues in cyclic products (Leikoski
et al., 2012). A 43-residue macrocycle could be a possible
product in Calothrix sp. PCC 7103 (Figure S3I). However, the
22-residue 8 is the largest confirmed product of a cyanobactin
pathway.
Enzymatic Reactions in Designed Unnatural Synthesis
RiPPs carry enormous potential for designer synthesis of deriv-
atives. As an initial examination of this process, we noted that
the large macrocycle 8 carries the PatA recognition sequence,
RSII. Recognition motifs within cyclic peptide scaffolds have
been shown to hold potential in stabilizing these scaffolds for
Figure 4. Manipulation of Reaction Order Alters Position of Heterocycle
In native cyanobactin biosynthesis, the order of enzymatic reactions starts with heterocyclization followed by N- and C-terminal proteolysis/macrocyclization,
such that in this study ThcD would act first followed by PatA and PatG. Here, we changed the order of the reaction such that proteolysis by PatA was carried out
after PatG macrocyclization of 2 to 8. This provided the linear product 13, which has its thiazoline ring (shown in yellow) shifted toward the N terminus from the
original C-terminal end position in the precursor 2.enhanced protein-protein interactions (Davidson et al., 2009;
de Vega et al., 2007). Thus, we expected that the macrocyclic
product 8 might be proteolyzed by PatA, which in turn would
produce a derivative with the thiazoline residue in an abnormal
position. The HPLC-purified product 8 (Figure S4A) was used
in assays with PatA, and the expected linear product 13 was
indeed observed (Figure S4B). A complete conversion to the
linear product 13was observed, as judged by the disappearance
of 8 in the mass spectrum. High-resolution FT-ICR MS/MS
confirmed the sequence of the product 13 (Figure S4B; Table
S2). In addition, PatA cleavage of both the cyclic substrate 8
and the linear substrate 2was comparable in that both reactions
were complete by 30 min (Figure S4C). Thus, proteolysis within
the cyclic peptidemotif shifts the position of the heterocycle (Fig-
ure 4). This holds potential for engineering thiazoline-containing
peptides, wherein heterocycles can be introduced readily in any
desired position within a linear peptide.
Cyclic Peptides from Full-Length Artificial
Precursor Peptides
Using the tru pathway in E. coli, we have synthesized many
peptides with highly artificial sequences (Ruffner et al., 2014;
Tianero et al., 2011). However, many sequences were not
accepted. Here, we asked whether these failures were due to
the cyanobactin enzymes, or to some limiting factor in E. coli.
We previously sought to use 14 in vivo, but no products were
detected. Peptide 14 encodes a precursor peptide sequence
derived from the natural pag pathway (Donia and Schmidt,
2011), but where the native INPYLYP has been replaced with
INPYLYC. Peptide 14 was a substrate for heterocyclization
in vitro but not macrocyclization in vivo (Sardar et al., 2014).
Many tru precursor peptides contain exceptionally strong
intra- or intermolecular disulfide bonds (McIntosh and Schmidt,
2010a, 2010b), necessitating use of the PatA-inhibiting DTT.
Therefore 14 and ThcD were allowed to react in the presenceChemistry & Biology 22,of DTT, affording 14a, which was purified by HPLC. Addition of
PatA led to production of 14b, which was then HPLC purified
and used with PatG, affording the expected cyclic product 14c
(cyc-INPYLYC*) (Figure 5). Minor amounts of the linearized
precursor (14c + H2O) were also produced. However, the yield
of 14cwas quite low in comparison with that from other reactions
performed in this study. The limiting factor was observed to be
macrocyclization by PatG (Figure S5). Therefore, at least in this
case, the factor limiting in vivo production appears to be the
macrocyclization reaction, since in vivo linear intermediates
would likely be non-specifically proteolyzed in the 5-day fermen-
tation time course.
Synthesis of Multiple Modified Cyclic Peptides in a
Single Reaction Batch from a Precursor Peptide
Carrying Multiple Cores
SomeRiPPpathways containmultiple core sequences in a single
precursor peptide. Apart from cyanobactins in which multiple
core sequences are very common, this feature has been
observed only rarely, such as in the cyclotide and orbitide family
of plant RiPPs (Arnison et al., 2013; Condie et al., 2011; Jennings
et al., 2001), and also the ustiloxins, fungal cyclic peptides that
havebeen recently reported tobe ribosomally synthesized (Ume-
muraet al., 2014; Tsukui et al., 2015).We therefore askedwhether
a precursor peptide (15) containing multiple cores could be pro-
cessed in vitro. Precursor15 is ahybrid containing core sequence
TFPVPTVC from the tru pathway and core sequence ACMPCYP
from the lyn pathway (McIntosh et al., 2013). Using the stepwise
methods applied to substrate 14, the expected products cyc-
TFPVPTVC* 15c and cyc-AC*MC*YP 15d (where C* is thiazoline)
were observed (Figures 6 andS6). As foundwith substrate 14, the
PatG reactionwas slow, and intermediates 15a and 15bwere not
fully cyclized within 24 hr. The linear derivatives of 15c and 15d
(15c-d + H2O) were not detectable in the reaction mixture. Cyclic
peptide 15d previously was not synthesized in vivo (Sardar907–916, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 911
Figure 5. Synthesis of Thiazoline-Contain-
ing pag Derivative from Full-Length Linear
Precursor
ThcD modification on 14 adds a thiazoline to
the core to yield 14a, which is followed by PatA
to yield 14b, which undergoes PatG processing
to lead to 14c. The structure of 14c is shown along
with its mass spectrum. The FT-ICR mass
spectrum is given in Figure S5 with a mass error
of <4.5 ppm. Structures and mass spectrum of
intermediates are also given in Figure S5. The
yellow circle represent thiazoline modification. It is
noteworthy that natural prenylagaramide (pag)
pathway products lack thiazolines, unlike the
unnatural derivative 14c.et al., 2014), again likely because of the slow reaction with PatG.
Overall, it is clear that application of the in vitro system comple-
ments the in vivo method when macrocyclization becomes rate
limiting.
Combining Posttranslational Modifications
from Multiple Pathways
RiPP prenylation has been found in the cyanobactins and
the quorum sensing ComX derivatives, where there are
many otherwise unprecedented posttranslational modifications
(Arnison et al., 2013; McIntosh et al., 2011; Okada et al., 2005).
We aimed to cross prenyltransferases between pathways,912 Chemistry & Biology 22, 907–916, July 23, 2015 ª2015 Elsevier Ltd All rights reservedswapping TruF1, from the trunkamide tru
pathway, and PagF, from the prenylagar-
amide pag pathway. Based on the natural
products of these pathways, one would
expect that TruF1 would reverse preny-
late serine and threonine, while PagF
would forward prenylate tyrosine.The cyclic peptides 15c and 15d were prenylated in a single
batch reaction containing both TruF1 and PagF, which led to
prenylated products cyc-TFPVPTVC* and cyc-AC*MPC*YP
(where the underlined threonine or tyrosine residue represents
prenylation and C* represents thiazoline). In the case of 15c
both singly and doubly prenylated products were observed on
the two threonine residues. For 15d carrying one tyrosine resi-
due, the expected single prenylation event was observed. In
addition, cyclic peptide 14c, which carries two tyrosine residues,
was doubly prenylated to yield 14d. In both cases the prenylation
reaction was complete in that the cyclic peptide substrate was
not detectable after 18 hr of reaction. The natural product analogFigure 6. Multiple Cyclic Peptides Produced
in a Single Reaction Batch from a Hybrid
Precursor Peptide Carrying Multiple Core
Sequences Derived from the tru and lyn
Pathways
As detailed for substrate 14, processing of 15 by
ThcD, PatA, and PatG led to the cyclic peptides
15c and 15d. The yellow circles represent thiazo-
line modifications. The schematics of the reaction
series are given along with the mass spectra of the
products. See Figure S6 for mass spectra and
structures of intermediates.
AB
Figure 7. DesignedCross-PathwayProducts
(A) Prenylation of cyclic peptides 15c and 15d by
a combination of the prenyltransferases TruF1
and PagF to yield the products 15e and 15f, and of
14c by PagF to yield the product 14d. Note that
15e is a natural product (patellin 6 from the tru
pathway), whereas 15f is a derivative of the lyn
pathway lacking thiazoline oxidation. The product
14d is an unusual derivative of the pag pathway
carrying thiazoline and double prenylation that is
natively absent in the parent pag natural product
(prenylagaramide B). The yellow and green circles
represent thiazoline and prenylation modifications
respectively.
(B) Mass spectrum of the product 14d.
See Figure S7 for the mass spectra of products
15e and 15f.of 14d (prenylagaramide B) does not carry a thiazoline modifica-
tion and is only singly prenylated, whereas in vitro exploitation of
these enzymes allows us to make this unnatural derivative.
These results show that it is possible to cross multiple posttrans-
lational modifications to create unusual products representing
hybrids of natural biosynthetic pathways (Figures 7 and S7).
DISCUSSION
Macrocycles are an underrepresented drug class, and their
potential is gradually being recognized. They exhibit unique
stability, membrane permeability, and ability to access difficult
targets such as protein-protein interactions. The cyanobactin
class of macrocyclic natural products provides access to an
unprecedented diversity of broad-substrate enzymes that can
be used for synthetic biology. The natural tru pathway has
previously been shown to be capable of producing millions of
macrocyclic derivatives using just proteinogenic amino acids
in vivo in an E. coli expression platform. Non-proteinogenic
amino acids have also been incorporated, greatly adding to
this already exceptional chemical diversity (Tianero et al., 2011).Chemistry & Biology 22, 907–916, July 23, 2015Here, we define practical methods
to make derivatives using mixtures
of cyanobactin enzymes in vitro. Both
natural and unnatural derivatives of the
patellamide, trunkamide, aestuaramide,
and prenylagaramide pathways were
successfully made. Moreover, the reac-
tions using 14 and 15 showed that these
are competent substrates, and that
a former lack of detection in E. coli
expression experiments (Sardar et al.,
2014) was not due to incompetency of
the tru pathway enzymes to accept
these substrates. Thus, in total the
enormous chemical potential of cyano-
bactin pathways determined through
in vivo work greatly underestimates the
potential products that can be synthe-
sized by this highly plastic biosynthetic
pathway.This work is complementary to a recent report wherein simple
derivatives of the patellamide core sequence were synthesized
in vitro (Houssen et al., 2014). The work described here synthe-
sizes highly distant sequences using the same set of enzymes,
including a hybrid of modifications from different pathways. In
addition, this work exploits the prenylation posttranslational
modifications, macrocycle size plasticity, and use of a one-pot
methodology. A combination of these technologies will find
use in the generation of important cyclic peptides other than cy-
anobactins. For example, the Suga laboratory produced hetero-
cyclic precursors to the telomestatins using an in vitro translation
system (Goto et al., 2014). Perhaps in combination with the
methods developed here more advanced telomestatin analogs
could be synthesized.
The cyanobactin macrocyclase PatG is a serine protease (Lee
et al., 2009; McIntosh et al., 2010; Agarwal et al., 2012; Koehnke
et al., 2012); its mechanism is similar to that of other serine pro-
teases in first creating a covalently tethered ester intermediate,
which is then displaced by a nucleophile. In the case of PatG,
that nucleophile is the N terminus, leading to macrocycle forma-
tion. In contrast, most serine proteases use water as theª2015 Elsevier Ltd All rights reserved 913
nucleophile. A remaining question was how this selectivity for
macrocyclization instead of hydrolysis is achieved. One proposal
is that a capping helix that binds to RSIII also excludes water
from the active site (Koehnke et al., 2012). However, nucleo-
philes readily enter the PatG active site (McIntosh et al., 2010;
Agarwal et al., 2012). For example, transamination can occur
via both side-chain and main-chain amines (McIntosh et al.,
2010), as well as from short dipeptides in the reaction buffer
(Agarwal et al., 2012). A peptide with a glycolate terminus
(containing OH in place of NH2 at the terminus) is hydrolyzed
efficiently by water (McIntosh et al., 2010). PatG could function
by exploiting native substrate preorganization that would
hold the amine terminus in proximity to the ester intermediate
(Milne et al., 2006). However, PatG has been used to cyclize
hundreds of vastly different substrates (Lee et al., 2009;
McIntosh et al., 2010; Agarwal et al., 2012; Koehnke et al.,
2012; Schmidt et al., 2005; Donia et al., 2006; Ruffner et al.,
2014; Tianero et al., 2011; Houssen et al., 2014). Here, PatG
efficiently macrocyclizes a 22-amino-acid precursor containing
much of the leader peptide. This peptide necessarily adopts a
shape very different from that of the small, natural substrates,
which is at odds with the idea of substrate preorganization.
Therefore, PatG itself likely scaffolds peptides for macro-
cyclization, preferring nitrogen to oxygen nucleophiles. The
role of protein-substrate interactions in promoting cyclization
versus hydrolysis is reminiscent of that found in non-ribosomal
peptide thioesterases, and should be further explored (Jiang
et al., 2011).
SIGNIFICANCE
Posttranslationally modified peptides are found in all forms
of life, and are increasingly important as drug leads and
biochemical tools. Nature provides an enormous diversity
of peptide products and posttranslational modifications.
Here, we demonstrate howenzymes frommultiple pathways
can be combined in vitro to produce new natural products
with tailored posttranslational modifications. Because cya-
nobactin enzymes are exceptionally promiscuous, these
combined enzymes could be applied to highly unnatural
substrates to design the synthesis of new compounds.
Such a strategy holds promise in applying the many RiPP
enzymes to the synthesis of drug-like compounds. Finally,
application of these enzymes provided new insights into
important and novel posttranslational modifications.
EXPERIMENTAL PROCEDURES
Genes and Cloning
The genes for the enzymes ThcD, PatA, PatG protease/macrocyclase domain,
and TruG, along with those for the substrates 14 and 15, were made previously
(Lee et al., 2009; Sardar et al., 2014). The codon-optimized version of TruF1
was obtained from GenScript. All enzymes and peptides were expressed as
histidine-tagged constructs in pET-28b (+) expression vectors.
Protein Expression, Purification, and/or Synthesis
Peptides 1 and 9were obtained from the Peptide Core facility at the University
of Utah. Precursor peptides 14 and 15 were made as described previously,
whereby R2D-BL21 cells were electroporated with the respective plasmid,
a seed culture grown overnight in 2xYT media, an aliquot of which was inocu-
lated the next day in 1 l of 2xYT cultures. The cultures were grown at 37C until914 Chemistry & Biology 22, 907–916, July 23, 2015 ª2015 Elsevier Lan OD600 of about 0.4 was achieved, followed by 1 mM isopropyl-b-D-thioga-
lactopyranoside (IPTG) induction for 3 hr at the same temperature. The
enzymes PatA, PatG, TruG, TruF1, and PagF were expressed such that all of
the conditions were maintained the same as above, except that 0.1 mM
IPTG induction was carried out overnight at a lower temperature of 18C.
The cells were harvested and purified by Ni-NTA affinity chromatography
under denaturing (for 14 and 15) or native (for all modification enzymes) condi-
tions, according to the manufacturer’s protocol (Qiagen). All peptides were
dialyzed, aliquoted, flash-frozen, and stored at 80C until use. The enzymes
were additionally stored in 10% (v/v) glycerol.
Assay Conditions for Sequential Enzyme Addition
In all assays a substrate concentration of 50–100 mMwasmaintained in 50mM
Tris buffer of pH 7.5. The heterocyclization reactions used 2 mM of the enzyme
in reaction mixtures containing 1 mM ATP and 5 mM MgCl2. The N-terminal
proteolysis reactions with PatA used 2–5 mM of the enzyme in reaction mix-
tures carrying 10 mM CaCl2, and C-terminal proteolysis/macrocyclization
with PatG or TruG used 10–20 mM of the enzymes with 5 mM MgCl2. Prenyla-
tion with TruF1 and PagF used enzyme at 10 mM in optimized reactionmixtures
containing 10 mM dimethylallyl pyrophosphate (DMAPP). A temperature of
37C with variable time points was used for all reactions. Reactions with sub-
strate 1 were carried out for 2 hr with ThcD, 2 hr with PatA, and overnight with
PatG/TruG and TruF1/PagF. With substrates 14 and 15, each step was carried
out for 18 hr (sometimes longer in reactions with PatG).
Assay Conditions for One-Pot Reactions
All reagents and enzymes were maintained at the same concentrations as
above, such as 50 mM Tris buffer (pH 7.5), 5 mM MgCl2, 10 mM CaCl2,
1 mM ATP, 2 mM ThcD, 2 mM PatA, and 10 mM PatG at 37C. If prenyltransfer-
ase was used, 10 mM of the enzyme was used with 10 mM DMAPP. Reactions
were carried out for 18 hr in most cases.
HPLC Purification of Reaction Intermediates
Reaction mixtures were centrifuged and the supernatant was used for purifi-
cation of intermediates by reverse-phase HPLC on a LaChrom Elite System
(Hitachi). A semi-preparative Supelco Discovery HS C18 column (25 cm 3
10 mm, 5 mm) was used for purification of the ThcD and PatA products of sub-
strate 1 (intermediates 2 and 4), and also for ThcD products of full-length sub-
strates 14 and 15, and PatA product of substrate 14a (intermediate 14b). A
gradient of 99% H2O/1% acetonitrile (ACN) to 1% H2O/99% ACN was used
over 20 min at a flow rate of 3.0 ml min1 with 250-ml injection volumes. No tri-
fluoroacetic acid was used in the mobile phase because of the possibility of
thiazoline ring opening. For PatA product intermediates of substrate 15 (inter-
mediates 15a, b) an analytical Agilent Eclipse XDB-C18 column (4.6 3
150 mm, 5 mm) was used. The same gradient as above was maintained, with
the exception of adding 0.05% formic acid to the aqueous mobile phase. Re-
actions were dried down to 100 ml for injection, and a flow rate of 0.7 ml min1
was used.
Characterization and Yield of Compounds
The reactions leading to 8were performed using the same reagent concentra-
tions described above, but were scaled up to 2 ml to guarantee sufficient
amounts of 1 (2 mg) for characterization. The product was purified as
described above to afford 1-mg quantities of pure 8, which was character-
ized by NMR and high-resolution MS. 1H NMR and 1H-1H COSY spectra
were obtained using a Varian INOVA 500 (1H 500 MHz) NMR spectrometer
with a 3-mm Nalorac MDBG probe. HSQC spectra were recorded on a Varian
INOVA 600 (1H 600 MHz and 13C 150 MHz) NMR equipped with a 5-mm 1H
[13C,15N] triple resonance cold probe with a z axis gradient, utilizing residual
solvent signals for referencing. The amount of isolated 8 was measured using
NMR standards consisting of varying concentrations of boc-tyrosine. Both
sample and standard were dissolved in 3:2 D2O/ACN-d3. To determine the
yield of 8 in enzyme reactions, the isolated, quantified standard was used to
generate a standard curve with HPLC on an analytical C18 column (Kinetex,
250 3 4.5 mm, 5 mm) over a gradient of 100% H2O-0.5% formic acid/0%
ACN-0.5% formic acid to 0% H2O-0.5% formic acid/100% ACN-0.5% formic
acid for 40 min at a flow rate of 1.0 ml min1.td All rights reserved
PatA Proteolysis Reaction on Macrocycle 8
HPLC-purified 8 was lyophilized and an aqueous stock solution of 1 mM was
made. PatA cleavage of 8 was carried out using 7 mM of the enzyme, 200 mM
purified 8, 4 mMMgCl2, and 10 mMCaCl2 at 37
C for 18 hr. A reaction without
PatA was used as a negative control.
LC-MS-Based Product Characterization
All product characterization was based on LC-MS analyses. Low-resolution
LC/ESI-MS was done using a Micromass Quattro-II (Waters) instrument on
an analytical Agilent Eclipse XDB-C18 column (4.6 3 150 mm, 5 mm) with a
linear gradient of 1%–99% B over 20 min, where the mobile phase consisted
of solvent A (H2Owith 0.05% formic acid) and solvent B (ACN). High-resolution
mass spectra were recorded using the same LC conditions on a Micromass
Q-TOF Micro Mass Spectrometer (Waters) in positive ion mode. FT-ICR/MS
was performed using an LTQ FT Ultra Hybrid Mass Spectrometer (Thermo
Scientific) at the University of Utah Mass Spectrometry Core Facility. See
Tables S3 and S4 for a complete list of all substrates, intermediates, and prod-
ucts made in this study along with their expected masses.
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